• systemic
  • Methods/Results -Using five different monoclonal antibodies (E29/anti-EMA, DF3, 139H2, VU-4H5, and SM3) that distinguish between various MUC1 glycoforms, high MUC1 expression (50-95% of tumour cells positive) was found in 13 of 17 anaplastic lymphoma kinase (ALK) positive systemic nodal ALCLs, and in one of 20 cases of classic HD. (bmj.com)
  • 7, 10, 12, 13 Morphologically, these lymphomas may closely resemble systemic ALCL, being also characterised by CD30 positive tumour cells with abundant cytoplasm, large irregular nuclei, and a prominent single nucleolus or multiple nucleoli. (bmj.com)
  • CD20
  • Prior CD20 immunophenotyping of tumors to document B cell NHL is acceptable. (clinicaltrials.gov)
  • Owing to its B cell lineage, it appears to be a potential target for treatment with the CD20 antibody rituximab. (icr.ac.uk)
  • In 1 patient with SD, however, persistence of CD20-positive cells within lymphoepithelial lesions was noted in spite of almost complete depletion of B lymphocytes from the normal gastric mucosa, suggesting either recirculation of MALT lymphoma cells to these lesions or defining lymphoepithelial lesions as a sanctuary site from rituximab penetration. (icr.ac.uk)
  • present
  • Antibodies detecting hypoglycosylated MUC1 were found to be absent in all lymphomas (SM3) or present in only six of 15 ALK positive ALCLs (VU-4H5). (bmj.com)